Nebenwirkungen · Kisplyx
Kisplyx 4 mg hard capsules Kisplyx 10 mg hard capsules · Abschnitt 4.8 · PDF-Seite 18
HOS-225035 · Präparat HOS-217386
In the pooled RCC population treated with lenvatinib and everolimus, GI perforation events were reported in 3.7% of patients (2.9% were Grade ≥3). In patients where data on individual drug modifications were collected, 2.1% of patients with GI perforations had dose modifications of lenvatinib (1.5% interruption and 0.6% reduction) and led to permanent treatment discontinuation in 1.1% of patients. The median time to onset of GI perforation events in lenvatinib plus everolimus- treated patients was 3.6 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-26T17:24:00Z · SHA-256 a44a00845e1c56c73ff53a9371d99e0ff78be7df90f4e83eb5595124e9e6b142 · Passage b9bc00ed43fcdb326d6023f48a4eae33174d75737d8c0ae8235af66debeab77d · Zeichen 28207–28721 im Abschnitt